Establishment and validation of an adherence prediction system for lifestyle interventions in non-alcoholic fatty liver disease

Table 1 Characteristics of enrolled subjects

Variable	Numerical value
Male, n (%)	49 (74.2)
Age (yr), mean ± SD	39 ± 12
Fatty liver disease course (month) (M, Q)	36 (9.0)
Smoking, n (%)	15 (22.7)
Likes fried food, n (%)	20 (30.3)
BMI (kg/m2), mean ± SD	28.4 ± 3.3
Waist-hip ratio, mean ± SD	0.9 ± 0.0
Abnormal blood pressure, n (%)	20 (30.3)
ALT (U/L) (M, Q)	64.5 (60.8)
AST (U/L) (M, Q)	36.0 (25.4)
GGT (U/L) (M, Q)	48.0 (44.0)
ALP (U/L) (M, Q)	78.0 (29.5)
TBIL (µmol/L) (M, Q)	14.7 (7.3)
FBG (mmol/L) (M, Q)	6.0 (0.9)
TG (mmol/L) (M, Q)	2.0 (1.3)
CHO (mmol/L), mean ± SD	5.0 ± 1.1
FINS (µU/L) (M, Q)	13.9 (8.2)
UA (µmol/L) (M, Q)	421.5 (116.5)
CAP (dB/m), mean ± SD	331.4 ± 33.0
LSM (kPa) (M, Q)	6.6 (2.9)
Walking (number of steps) (M, Q)	4519.0 (4564.5)
Reduction in caloric intake (kcal) (M, Q)	68.0 (127.8)

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: Gamma-glutamyl transferase; ALP: Alkaline phosphatase; TBIL: Total bilirubin; TG: Triglyceride; TC: Total cholesterol; UA: Umbilical artery; BMI: Body mass index; FBG: Fasting blood glucose; FINS: Fasting insulin; CAP: Controlled attenuation parameter; LSM: Liver stiffness measurement.